| Market Capitalization (Millions $) |
91,694 |
| Shares
Outstanding (Millions) |
113 |
| Employees |
10,368 |
| Revenues (TTM) (Millions $) |
13,097 |
| Net Income (TTM) (Millions $) |
3,991 |
| Cash Flow (TTM) (Millions $) |
-1,345 |
| Capital Exp. (TTM) (Millions $) |
619 |
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc is a biotechnology company that specializes in developing and commercializing innovative medicines for serious medical conditions. The company was established in 1988, and since then it has grown tremendously to become one of the most notable biotech companies in the world.
Regeneron's headquarters are based in Tarrytown, New York, where it has a sprawling 579-acre research and development center. The company has over 8,000 employees worldwide, including scientists, researchers, and clinicians, who work tirelessly to advance medical research and develop novel medicines.
Regeneron has a wide portfolio of products that include treatments for a range of conditions such as age-related macular degeneration, diabetic macular edema, atopic dermatitis, asthma, and cancer. The company is known for developing biologics, which are drugs that are made using living organisms. Regeneron's proprietary technology and production methods have enabled it to create highly effective and safe biologic treatments that have transformed the lives of many patients.
One of Regeneron's most well-known products is Eylea, a drug that treats age-related macular degeneration, a leading cause of blindness in older adults. Regeneron's second drug, Dupixent, is used for the treatment of moderate-to-severe atopic dermatitis in adults.
Regeneron is also active in the fight against COVID-19. The company developed a novel therapy called REGEN-COV, which is a combination of two monoclonal antibodies that have been shown to reduce hospitalization and death in COVID-19 patients. Regeneron has received approvals for this therapy from several regulatory bodies around the world and is now being widely used in the US and other countries.
In conclusion, Regeneron Pharmaceuticals Inc is a pioneering biotechnology company that is committed to developing innovative and effective treatments for serious medical conditions. The company's dedication to research, development, and patient care has made it a leader in the biotech industry and an important player in the fight against diseases.
Company Address: 777 Old Saw Mill River Road Tarrytown 10591 NY
Company Phone Number: 847-7000 Stock Exchange / Ticker: NASDAQ REGN
| REGN is expected to report next financial results on February 05, 2024. |
|
|
